**SPEC BUY**

Current Price  $0.06  
Market Cap.  $24.5m

**Ticker:** BOT.ASX  
**Sector:** Biotechnology

| Shares on Issue (m): | 408.8 |
| Market Cap ($m): | 24.5 |
| Net Debt / (Cash) ($m): | -2.4 |
| Enterprise Value ($m): | 22.2 |
| 52 wk High/Low: | 0.07 0.02 |
| 12m Av Daily Vol (m): | 1.21 |

**Financials:**

| Op CF ($m) | 4Q16A 1Q17A 2Q17A |
| Inv CF ($m) | 0.0 0.0 0.0 |
| Fin CF ($m) | 3.2 -0.1 0.0 |
| Net CF ($m) | 3.2 -0.5 -0.8 |
| Cash ($m) | 3.7 3.1 2.4 |

**Top Five Shareholders:**

| Matthew Callahan | 17.3% |
| Henry Bosch | 3.7% |
| Nutsville Pty Ltd | 3.1% |
| Osagie Imasogie | 1.3% |
| Cabletime Pty Ltd | 1.2% |

**Shareholder Structure:**

| Board | 23% |
| Escrowed (incl. board shares) | 41% |
| Free Float | 39% |

**Company Summary:** Botanix (BOT) is a small biotech company focused on developing new topical drugs for the treatment of serious skin disease. The Company's development products focus on the use of a synthetic cannabidiol active with a novel drug delivery system (called Permetrex). Initially BOT will focus on its flagship product, BTX-1503, for the treatment of acne.

**Quick Read**

We initiate coverage of BOT with a speculative buy call. BOT's flagship product, using a synthetic cannabidiol based active, has the potential to be a ‘game-changing’ treatment for moderate to severe acne, a global market currently valued at over US$4bn. Significantly, the Company is investigating potential pipeline products that pair its Permetrex drug delivery technology with on-the-market active ingredients to generate early revenues (these reformulations will not require FDA approval).

**View | Positive**

**Sizeable global markets:** The global prescription acne market is estimated to generate revenues of over US$4bn per year. Epiduo, currently the top-billed prescription acne treatment, had estimated sales of over US$350m in 2016. It is these large potential revenues that BOT is chasing with the Company’s flagship product, BTX-1503.

**First in class:** No currently marketed topical treatment for acne reduces or influences the production of sebum (the cause of oily skin and acne). Evidence suggests that cannabidiol has the potential to influence sebum production, and as such BTX-1503 may possibly become a ‘first-in-class’ topical treatment for moderate to severe acne.

**FDA approvals process:** As with all small biotech companies, substantial resources of time and money are required to meet FDA approval requirements to bring a drug to market. Maintaining sufficient funding through the clinical trials process is critical to BOT’s success and will ultimately provide the basis for potential returns to investors in the future.

**Unlocking value:** BOT is exploring ways to unlock value by leveraging its worldwide exclusive license to the Permetrex drug delivery technology. By pairing Permetrex with already approved active ingredients, BOT sidesteps the FDA approvals process and is able to market these drugs in a much shorter time period (compared to new drugs with new active ingredients requiring Phase 1 to 3 clinical trials).

**Restricted substance:** BOT also faces regulatory constraints on the import, export and use of synthetic cannabidiol as it’s a controlled substance according to US and Australian drug enforcement laws. Whilst the use of cannabidiol for medical purposes is permitted, BOT must tick all the boxes with regulatory agencies to guarantee that the Company’s progress is not halted by drug enforcement authorities.

**Recommendation**

Although it is premature to forecast revenues or cash flows, we believe the potential prize is sufficiently large to warrant a speculative buy call.
Executive Summary

**Product pipeline:** BOT’s pipeline of products focus on the topical treatment of serious skin diseases using cannabidiol as the active ingredient. The cannabidiol active is driven deep into the skin using a novel drug delivery technology called *Permetrex*. Initially BOT is concentrating on trialling a formulation of cannabidiol and Permetrex, called *BTX-1503*, for the treatment of acne. Additionally, BOT is investigating pairing Permetrex with already approved active ingredients in new formulations that will not need to undergo the lengthy FDA approvals process.

**Large global markets:** BOT’s target markets are large, and are expected to continue to grow with sustained global population growth. The global prescription acne market is expected to grow to over US$4.5 billion by 2018. Competing products in the prescription acne treatment market have generated substantial revenues in recent years; with revenues for the top-billed product, Epiduo, expected to exceed US$350 million for 2016.

**Value for investors:** Large pharmaceutical companies are constantly seeking to shore up their pipeline of new products by acquiring small biotech companies. 493 deals were completed in 2015 at an average value of over US$500 million per transaction. Recent deals in the dermatology space have ranged from US$90 million for Allergan’s acquisition of Anterios to upwards of US$5 billion for Pfizer’s acquisition of Anacor.

**Stage of development:** BOT has progressed its flagship product (BTX-1503) through discovery and pre-clinical development, with Phase 1 trials expected to commence in CY2017. Pipeline products for the treatment of psoriasis (BTX-1308) and atopic dermatitis (BTX-1204) are yet to progress past the initial discovery phase.

**Regulatory hurdles:** Obtaining *FDA approval*, through Phase 1, 2 and 3 clinical trials, can be a long and arduous task with many hurdles to overcome along the way. The FDA themselves state that the approvals process can take anywhere from 2 to 7 years and there is only a 6-7% chance of successfully getting a drug to market. BOT has to navigate the approvals process whilst also meeting the demands of drug agencies in Australia and the US due to cannabidiol being registered as a *restricted substance* (as it is derived from the cannabis sativa plant).

**Key personnel:** BOT has assembled a *strong board* with impressive experience in developing new drugs for the skin care market. The Company’s strong relationship with Dr Eugene Cooper, the inventor of Permetrex and holder of its patent, sets a solid foundation for developing potential future pipeline products leveraging the Permetrex drug delivery vehicle.
Development Products

BOT’s core business is generating new topical drugs for the treatment of common serious skin diseases (e.g. acne, psoriasis, eczema). The Company’s development products focus on the use of a synthetic cannabidiol active with a novel drug delivery system (called Permetrex).

The ‘endocannabinoid system’, which regulates skin function, growth and renewal, consists of receptors that are configured only to accept cannabinoids, especially tetrahydrocannabinol (THC) and cannabidiol (CBD). It is believed that cannabidiol may play a significant role in modulating the endocannabinoid system of receptors; potentially normalising unwanted skin growth, reducing excessive production of oils and reducing inflammation and infection, among other functions.

Permetrex™

Although there is published scientific support for the potential benefits of cannabidiol as a treatment for serious skin diseases, the active’s development into marketable products has been inhibited by its ineffectiveness at distributing across the skin and penetrating the epidermis. Permetrex addresses this limitation of cannabidiol by super-concentrating the drug on the skin, driving it deeper into the dermis.

Figure 1: Permetrex action in driving actives deeper into the skin

Although BOT does not own the patent for Permetrex, it does have worldwide exclusive rights to its use with any drug actives that can be used to treat skin diseases. The Permetrex license provides opportunities for BOT to expand its pipeline of novel skin disease treatments.

The chemicals that make up Permetrex are on the FDA approved inactive ingredients list, meaning that Permetrex may be combined with already approved active ingredients without undergoing lengthy FDA approved clinical trials. This presents the opportunity for BOT to generate revenues and cash flows in a much shorter time-frame than other biotech companies developing new products. The only conditions being that the active must be dosed in similar amounts as previous formulations and the drug shall be purposed for
The time to market for these reformulated drugs is estimated to be approximately 12 months. This provides potential early revenue for BOT as the Company proceeds its cannabidiol based products through Phase 1 clinical trials.

A study testing the safety and irritability of Permetrex found that the delivery technology has “minimal or weak irritancy potential” and no safety issues. These results de-risk BOT’s pipeline of skin disease treatments and pave the way for the Company to begin reformulating existing drugs using the Permetrex vehicle. BOT recently announced that it has filed 5 new patent applications covering Permetrex enabled products; some of which are aimed at protecting new formulations of currently approved actives.

Permetrex is patented by Dr. Eugene Cooper, who in turn licenses it to BOT for worldwide exclusive use with any active that can be used to treat skin diseases. Under the terms of the licensing agreement BOT must pay Dr Cooper a royalty of 5% of net sales of each licensed product utilising the Permetrex drug delivery system. BOT must also pay Dr Cooper the following fixed milestone lump sums:

1. US$50,000 upon commencement of the first human trial of a licensed product;
2. US$50,000 upon acceptance of filing for regulatory approval for the manufacture, distribution, use and sale of the first licensed product; and,
3. US$100,000 upon the receipt of regulatory approval for the manufacture, distribution, use and sale of the first licensed product.

**Acne Treatment (BTX-1503)**

There has been little innovation in the field of acne treatment in recent times, with all “new” products entailing reformulations and rebranding of existing acne treatments. BOT’s lead product, BTX-1503, seeks to address significant unmet demand in the sizeable global prescription acne market. The global acne prescription market is expected to reach ~US$4.5 billion by 2018. The top branded topical prescription product, Epiduo, generated revenues of ~US$330 million in 2013.

**Figure 2: BTX-1503 planned positioning versus existing acne products**

<table>
<thead>
<tr>
<th></th>
<th>BTX-1503</th>
<th>Clindamycin</th>
<th>Topic Retinoid</th>
<th>Minoxidil</th>
<th>Erythromycin</th>
<th>Accutane</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduces Sebum</td>
<td>✓</td>
<td>✗</td>
<td>✓</td>
<td>✗</td>
<td>✗</td>
<td>✓</td>
</tr>
<tr>
<td>Anti-inflammatory</td>
<td>✓</td>
<td>✗</td>
<td>✓</td>
<td>✗</td>
<td>✗</td>
<td>✓</td>
</tr>
<tr>
<td>Anti-microbial</td>
<td>✓</td>
<td>✗</td>
<td>✓</td>
<td>✗</td>
<td>✗</td>
<td>✓</td>
</tr>
<tr>
<td>Topical</td>
<td>✓</td>
<td>✗</td>
<td>✓</td>
<td>✗</td>
<td>✗</td>
<td>✓</td>
</tr>
<tr>
<td>Minimal side effects</td>
<td>✓</td>
<td>✗</td>
<td>✓</td>
<td>✗</td>
<td>✗</td>
<td>✓</td>
</tr>
</tbody>
</table>

Source: BOT investor presentation

Currently, no topical acne treatment influences sebum (skin oils) production or the physiochemical properties of sebum; BTX-1503 aims to be the first topical acne treatment to do so. Reducing sebum production is the most effective method of treating acne and is currently the domain of the leading oral product (isotretinoin or ‘Accutane’); which has
considerable side effects, including potential birth defects, depression or liver damage, among others. It is the aim of BOT for BTX-1503 to have the efficacy of Accutane, without the potentially serious side effects.

The drug active for BTX-1503 will be a synthetic form of the naturally occurring cannabidiol. By synthetically manufacturing cannabidiol, BOT can produce a 100% pure product that can be scaled up more readily than extracting naturally from the Cannabis Sativa plant. Synthetic cannabidiol is a “Schedule I” drug substance under the Controlled Substances Act (US) and is subject to strict control and regulation by the DEA. Accordingly, BOT has secured the use of Sharp Clinical Services facilities, in Pennsylvania, to develop BTX-1503. Sharp’s facility is licensed with the DEA and FDA to handle “Schedule I” substances. Additionally, BOT has received an import permit from the DEA to import cannabidiol into the US for its drug development activities.

The majority of the BTX-1503 formulation will consist of the Permetrex drug delivery system, which has already been shown to have “minimal or weak irritancy potential” and no safety issues in trials completed in December 2016. BOT expect to complete the Phase 1a safety study and Phase 1b acne pilot study for BTX-1503 in the next 6-7 months.

Pipeline Products
BOT’s pipeline products similarly use a cannabidiol drug active, leveraging the Permetrex drug delivery technology to penetrate the active deep into the skin. BOT has flagged two additional pipeline products to treat plaque psoriasis (BTX-1308) and atopic dermatitis (BTX-1204).

Plaque Psoriasis (BTX-1308): According to the World Health Organisation the prevalence of psoriasis in the United States is approximately 3.3%, meaning that over 10 million people in the United States are living with psoriasis. Many of those have plaque psoriasis. The current treatment for the disease is injectable biologics, with BOT stating that the cost of these treatments in 2014 was $20 billion. These biologics have potentially serious side effects such as serious nervous system disorders (e.g. multiple sclerosis), blood disorders or certain types of cancers (e.g. lymphoma). BOT believes that BTX-1308 may be able to treat the signs and symptoms of psoriasis without incurring the serious side effects of existing on-market drugs.

Atopic Dermatitis (BTX-1204): It is estimated that approximately 31 million people have atopic dermatitis in the United States. This comes at an estimated annual cost for treatment of $3.8 billion. Current treatments have been shown to potentially cause serious side effects, including thinning of the skin and loss of barrier function as well as the potential to induce cancer. BTX-1204 may be able to control inflammation and improve skin barrier function in atopic dermatitis sufferers whilst avoiding the aforementioned side effects.
Global Skin Disease Markets

The majority of the global population will be affected by some form of skin disease in their lifetime. At any one time, acne is estimated to affect up to 9% of the global population, making it the eighth most prevalent disease worldwide. The American Academy of Dermatology believes that it affects more than 50 million Americans annually. The prevalence of psoriasis is estimated to be between 1% and 5% globally, with at least 100 million individuals affected worldwide (according to the World Health Organisation). And atopic dermatitis (or Eczema) affects up to 20% of children and up to 3% of adults; with recent data showing prevalence is increasing, especially in low-income countries.

BOT’s flagship product (BTX-1503) aims to be a first-in-class topical acne treatment, addressing one of the largest skin disease markets. The global prescription acne market is expected to reach US$4.5 billion by 2018, up from estimated revenue of ~US$4 billion in 2013. BOT’s top branded potential competitors generated revenues of between US$85-US$331 million in 2013. In 2016 sales of Epiduo are expected to exceed US$350 million.

Sales of Epiduo are expected to reach US$350m in 2016

The global skincare industry is expected to grow to over US$150bn by 2021

Figure 3: Annual revenues for top branded prescription topical acne treatments

Source: BOT releases

BOT’s pipeline products (BTX-1308 and BTX-1204) also address sizeable markets. The leading treatment for psoriasis came at a cost of US$20 billion in 2014, whilst the annual cost of treating atopic dermatitis in the US is US$3.8 billion. More broadly, revenues in the global skincare market are projected to rise to over US$150 billion by 2021 at a compound annual growth rate of approximately 5%.

Figure 4: Global skincare revenue projections through 2021

Source: BOT releases
Revenue Model and Earnings Potential

Generating income

BOT has two potential sources of revenue for its dermatological products:

1. License milestones and royalties from agreements to license or partner its portfolio of pipeline products; and,

2. Sales revenue from the commercialisation of approved dermatological products.

There is a significant time lag between product development and potential income due to the onerous FDA approvals process. BOT is aiming to significantly reduce the time required for drug approval, providing earlier opportunities for income from partnering or licensing agreements. However, commencement of Phase II clinical trials is still up to 12 months away for BOT’s flagship product (BTX-1503). This suggests that potential partnering opportunities and associated income will not occur in the near term.

Take-over Target

The other option is for BOT to strike a deal with a larger biotech or pharmaceuticals company to acquire BOT’s pipeline products. Such deals can be substantial in size and provide potential early returns for investors in biotech companies. A study of M&A deal value between 2005 and 2012 shows that deal value increases significantly as a product is progressed through the stages of clinical development.

Figure 5: Price distribution of biopharma M&A deals

According to HBM Partners, 2015 saw approximately US$250 billion worth of M&A deals in the biopharma space, up 8% on 2014. The number of deals completed increased from 371 in 2013 and 438 in 2014, to 493 deals in 2015; meaning the average value of deals in 2015 was over US$500 million. Such M&A activity highlights the efforts of big pharma to shore up their future revenue as they face generic drug competition in a period where their products are coming off patent.
Recent deals in the dermatology space have ranged from US$90 million for Allergan’s acquisition of Anterios, with products in pre-clinical development, to upwards of US$5 billion for Pfizer’s acquisition of Anacor, with products about to go to market after completing Phase III clinical trials.

**Figure 6: Recent biotech deals in the dermatology space**

<table>
<thead>
<tr>
<th>Deal</th>
<th>Treatments</th>
<th>Deal Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergan acquired Vitae Pharmaceuticals in October 2016</td>
<td>Oral psoriasis treatment (VTP-43742), in Phase II clinical trials</td>
<td>US$639m</td>
</tr>
<tr>
<td></td>
<td>Topical atopic dermatitis treatment (VTP-38543), in Phase II clinical trials</td>
<td></td>
</tr>
<tr>
<td>Sienna Biopharmaceuticals acquired Creabilis in December 2016</td>
<td>Topical psoriasis treatment (CT327), in Phase IIb clinical trials</td>
<td>US$150m</td>
</tr>
<tr>
<td></td>
<td>Topical atopic dermatitis treatment (CT340), in pre-clinical development</td>
<td></td>
</tr>
<tr>
<td>Allergan acquired Anterios in January 2016</td>
<td>Topical drug delivery technology (NDS™)</td>
<td>US$90m</td>
</tr>
<tr>
<td></td>
<td>Topical acne treatment (ANT-1207), in pre-clinical development</td>
<td></td>
</tr>
<tr>
<td>Leo Pharma acquired Astells global dermatology business in April 2016</td>
<td>Topical atopic dermatitis treatment (Protopic®), currently on the market.</td>
<td>US$770m</td>
</tr>
<tr>
<td></td>
<td>...among other products for the treatment of acne and skin infections</td>
<td></td>
</tr>
<tr>
<td>Pfizer acquired Anacor in May 2016</td>
<td>Topical atopic dermatitis treatment (Crisaborole), completing Phase III clinical trials</td>
<td>US$5.2b</td>
</tr>
<tr>
<td>Purdue acquired drug rights from Exicure in December 2016</td>
<td>Topical psoriasis treatment (AST-005), completed Phase I clinical trials</td>
<td>US$790m</td>
</tr>
</tbody>
</table>

Source: pharmamedtechbi.com

Several large deals were completed in 2016 in the dermatology space.
BOT is progressing BTX-1503 through pre-clinical development towards FDA approved clinical trials.

Stage of Development

BOT has progressed its flagship product (BTX-1503) through discovery and pre-clinical development, with Phase 1 trials expected to commence in CY2017. Pipeline products for the treatment of psoriasis (BTX-1308) and atopic dermatitis (BTX-1204) are yet to progress past the initial discovery phase.

Figure 7: Product development stages

<table>
<thead>
<tr>
<th>Product</th>
<th>Current Applications / Study</th>
<th>Stage of Development</th>
<th>Regulatory targets</th>
<th>Source: BOT releases</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTX-1503</td>
<td>Acne treatment</td>
<td>Discovery</td>
<td>Commence Phase 1a studies</td>
<td></td>
</tr>
<tr>
<td>BTX-1308</td>
<td>Plaque psoriasis treatment</td>
<td>Pre-clinical</td>
<td>FDA Phase I, II and III Processes; FDA Approval</td>
<td></td>
</tr>
<tr>
<td>BTX-1204</td>
<td>Atopic dermatitis treatment</td>
<td>Clinical</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Argonaut expectations based on Company commentary

Figure 8: BTX-1503 timeline towards clinical trials

- Phase I trials for BTX-1503 are expected to commence in the coming months.
- BOT has patent applications covering BTX-1503 and its suite of pipeline products.
- BOT has licenses with Dr Eugene Cooper for the use of Permetrex and with Sharp Clinical Services for the production of cannabidiol.

BOT has the following patent applications in progress, protecting its suite of pipeline products:
- 5 new patent applications “covering Permetrex enabled products”; some of which are aimed at protecting new formulations of currently approved actives, and the others which protect additional uses for the Company’s drug active, synthetic cannabidiol.

BOT has secured a worldwide exclusive license for the use of Permetrex for the topical treatment of skin diseases; protecting the Company’s pipeline products and adding potential new income streams from pairing Permetrex with already approved actives. The Company has also signed a services agreement with Sharp Clinical Services, Inc (licensed by the FDA and DEA to handle “Schedule I” substances) for the supply of cannabidiol and access to Sharp’s facilities for clinical development purposes.
Risks

Cash Flows and Funding
BOT’s cash expenditure has been slowly ramping up to accommodate BOT’s progress of its flagship BTX-1503 product. We estimate that as BOT proceeds through the FDA approvals process, spending will increase accordingly. At current and forecast cash burn rates BOT will require additional funding at some point in CY2017.

Figure 9: BOT’s quarterly cashflows since backdoor listing

<table>
<thead>
<tr>
<th>Cash Flow ($'000's)</th>
<th>4Q16</th>
<th>1Q17</th>
<th>2Q17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receipts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payments</td>
<td>-113</td>
<td>-414</td>
<td>-761</td>
</tr>
<tr>
<td>R&amp;D tax rebate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest</td>
<td>2</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Other</td>
<td>-4</td>
<td>-2</td>
<td>1</td>
</tr>
<tr>
<td>Operating Cash Flow</td>
<td>-115</td>
<td>-415</td>
<td>-755</td>
</tr>
<tr>
<td>Investing Cash Flow</td>
<td></td>
<td></td>
<td>33</td>
</tr>
<tr>
<td>Financing Cash Flow</td>
<td>3,241</td>
<td>-116</td>
<td></td>
</tr>
<tr>
<td>Net Cash Flows</td>
<td>3,159</td>
<td>-531</td>
<td>-755</td>
</tr>
<tr>
<td>Opening Cash</td>
<td>493</td>
<td>3,652</td>
<td>3,121</td>
</tr>
<tr>
<td>Closing Cash</td>
<td>3,652</td>
<td>3,121</td>
<td>2,366</td>
</tr>
</tbody>
</table>

Source: BOT releases

Figure 10: BOT operating cashflow and closing cash position (forecast for 3Q17)

Source: BOT releases

Cash flows and funding are critical to BOT’s ability to progress through FDA clinical trials

At current cash burn rates, BOT will need to raise additional funds at some point in CY2017

BOT’s operational cash burn has steadily increased as it moves towards commencing Phase I clinical trials for BTX-1503
Timing
The key risk to investors in small biotech companies is the lengthy timelines required to gain FDA approval for new drugs. For dermatological indications, progressing through the FDA approvals process costs on average about US$24m and takes anywhere from 2-8 years. Maintaining sufficient funding through initial stages of the FDA approvals process is critical to BOT advancing its products to a stage where it attracts the interest of potential partners. BOT is targeting the start of FY18 for initiating Phase 1 testing of BTX-1503.

Through Permetrex, BOT is targeting early revenue by pairing it with existing active agents; avoiding the FDA clinical trial process. However, the reformulation process will still take up to 12 months to develop a marketable product. BOT then need to market the new formulation and seek potential partners to distribute the product adding further time between product reformulation and first revenues.

The arduous process for demonstrating safety and efficacy of a product, through the FDA approvals process, takes significant amounts of time and money. As with all biotech companies, it is imperative that BOT maintain a strict schedule through this process to avoid potential budget blowouts which could eat away at the Company’s cash balance and delay or potentially derail the advancement of BOT’s pipeline products.

Technical
BOT’s success, and investors’ returns, hinge on the efficacy of its development products in treating serious skin disease. In particular, the ability of cannabidiol to influence sebum production and reduce inflammation in the skin is paramount to BOT’s future appeal to large pharmaceutical companies as a potential take-over target.

A lack of new drugs for the treatment of acne over the past decade has opened a gap for BTX-1503 to be a ‘first-in-class’ acne treatment. Progressing through the clinical trials as quickly as possible and proving efficacy of BTX-1503 is therefore critical to maintain the Company’s competitive advantage over other new acne treatments undergoing clinical trials.
Regulatory

Clinical trials
BOT has completed a safety and irritation clinical trial for Permetrex with results showing “minimal or weak irritancy potential” and no safety issues when the drug is applied to the skin. The Permetrex results de-risk the impending BTX-1503 clinical trials as Permetrex makes up the majority of the BTX-1503 formula. BTX-1503 is on schedule to commence Phase I testing in the first half of CY2017.

Figure 11: FDA clinical trial process explained

<table>
<thead>
<tr>
<th>Phase</th>
<th>Participants</th>
<th>Period</th>
<th>Success Rate</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase Ia</td>
<td>20 - 100</td>
<td>Several months</td>
<td>~70%</td>
<td>Assesses safety and tolerability to single doses of the drug</td>
</tr>
<tr>
<td>Phase Ib</td>
<td>100 - 300</td>
<td>Several months to 2 years</td>
<td>~33%</td>
<td>Assesses safety and tolerability to multiple doses of the drug</td>
</tr>
<tr>
<td>Phase IIa</td>
<td>300 - 3,000</td>
<td>1 to 4 years</td>
<td>~25-30%</td>
<td>Dosing - how much of the drug should be given?</td>
</tr>
<tr>
<td>Phase IIb</td>
<td></td>
<td></td>
<td></td>
<td>Efficacy - how well does the drug work at the prescribed doses</td>
</tr>
</tbody>
</table>

Source: FDA website

Patent protection
BOT has two separate provisional patent applications for its “topical composition and use thereof for the treatment of acne” protecting BTX-1503 in Australia and the USA. The provisional patent applications provide the filing date for all subsequent patent applications worldwide, protecting BOT’s IP internationally.

BOT has also filed 5 new patent applications “covering Permetrex enabled products”; some of which are aimed at protecting new formulations of currently approved actives, and the others which protect additional uses for the Company’s drug active, synthetic cannabidiol.
The patent for Permetrex is held by its inventor, Dr Eugene Cooper, who in turn licenses the product to BOT.

Synthetic cannabidiol is a controlled substance in both Australia and the US.

BOT is required to fulfil several regulatory obligations to conduct clinical trials with the controlled cannabidiol active.

Legal experts see no inherent issues in BOT’s plan to conduct trials with cannabidiol in Australia and the US.

The patent for Permetrex is held by Dr Eugene Cooper, who in turn has granted BOT a license for exclusive worldwide use of the drug delivery technology when used with any drug active purposed for the topical treatment of any skin disease. It is the responsibility of Dr Cooper to enforce and defend his intellectual property rights with respect to Permetrex. Any failure to do so, on Dr Cooper’s behalf, may present a significant risk to BOT and its wider portfolio of pipeline products.

Restricted substances

Synthetic cannabidiol, the drug active in BOT’s current pipeline of products, is a restricted substance in both the US (cannabidiol is a Schedule I substance under the CSA) and Australia (cannabidiol is a Schedule 4 substance under CPI regulations).

BOT has already received an import license from the DEA to import cannabidiol into the US. Additionally, BOT has contracted with a specialised Good Manufacturing Practice (GMP) facility, which is licensed by the FDA and DEA to handle Schedule I substances, to provide clinical development services for the production of BTX-1503.

In Australia: Cannabidiol is a Schedule 4 restricted substance under CPI regulations. Therefore, BOT require licenses and the necessary permits to import BTX-1503 for clinical trial purposes. It is unlawful in Australia to import, export, manufacture or supply any medicine that is not registered with the Australian Register of Therapeutic Goods (ARTG). To register a drug with the ARTG, BOT must obtain a Clinical Trial Notification (CTN), which essentially grants approval for the clinical trial in Australia. After obtaining a CTN, BOT should have sufficient leverage to be granted the necessary import licenses and permits for its cannabidiol based medicines.

In the US: Cannabidiol is a Schedule I substance under the Controlled Substances Act (CSA), enforced by the DEA. In order to conduct clinical trials with a Schedule I substance, BOT must first obtain a registration under the CSA from the DEA. To receive such a registration, BOT must demonstrate that it is a qualified researcher and competent to conduct the proposed trials, as determined by the Department of Health and Human Services.

According to legal experts in both Australia and the US, there are no inherent issues with BOT’s proposed conduct of a clinical trial of a topical formulation of cannabidiol if the Company fulfils all of its regulatory requirements with respect to the restricted nature of the cannabidiol active.
The board has a track record of taking medical products and technologies from the R&D phase through regulatory approvals to commercialisation.

Key Personnel

Board of Directors

Graham Griffiths, Non-Executive Director & Chairman: Mr Griffiths has an executive career in technology based companies that spans over 39 years. In 2000, Mr Griffiths became Managing Director of ASX listed company ipernica Ltd, a diversified technology and intellectual property commercialisation group. During this time, he oversaw the successful acquisition of Nearmap Ltd (ASX: NEA).

Matthew Callahan, Executive Director: Mr Callahan is the founding CEO of iCeutica Inc and a co-inventor of some of the technologies that comprise the Submatrix Fine Particle Technology™ for improving the bioavailability of pharmaceuticals. iCeutica has developed 3 products to date that have received FDA approval. He has more than 20 years legal, licensing and investment management experience and is also a Director of Glycan Bioscience LLC and a founding director of ASX listed Orthocell Ltd (ASX: OCC).

Dr Bill Bosch, Executive Director & Chief Scientific Adviser: Dr Bosch has more than 20 years experience in the pharmaceutical industry, focusing on applications of nanotechnology to drug product development. Dr Bosch also works with iCeutica Inc and is a co-inventor of the SoluMatrix™ technology and has been instrumental in the development and scale up of the platform and the development of the 3 FDA approved products that use the SoluMatrix™ drug delivery technology.

Robert Towner, Non-Executive Director: Mr Towner has over 20 years’ corporate advisory and executive experience in the financial markets. Mr Towner is the founder and sole director of Cornerstone Corporate Pty Ltd, a corporate advisory company. Mr Towner’s prior board experience includes serving as; a founding Executive Director of bioMD Limited, playing a major role in the merger of bioMD Limited with then-private Allied Health Care Limited to create Admedus Limited (ASX: AHZ); and, an Executive Director of Triangle Energy (Global) Limited (ASX: TEG).

Consultants

Dr Eugene Cooper: Dr Cooper is the inventor and patent-holder of the Permetrex topical drug delivery system used by BOT in its product formulations. Dr Cooper also co-invented the NanoCrystal® drug delivery technology, which has been used in six products approved by the FDA.

Professor Diane Thiboutot and Emeritus Professor James Leyden: Prof Thiboutot and Prof Leyden have been engaged by BOT to help guide the development of BOT’s product candidates. They are two of the leading acne researchers and clinicians in the US and have been involved in the development of numerous skin disease products.

Dr Michael Thurn, Chief Operating Officer: Dr Thurn has unique experience in drug development, having recently led development of a topical treatment for acne being developed by venture capital backed company Mimetica. The relationships forged in his role at Mimetica will be invaluable to BOT as it progresses the FDA clinical trials for BTX-1503.
RESEARCH:
Ian Christie | Director, Industrial Research
+61 8 9224 6872 ichristie@argonaut.com

Matthew Koane | Director, Metals & Mining Research
+61 8 9224 6869 mkoane@argonaut.com

James Wilson | Analyst, Metals & Mining Research
+61 8 9224 6850 jwilson@argonaut.com

Helen Lau | Analyst, Metals & Mining Research
+61 3 5577 4804 hlau@argonaut.com

Daniel Williamson | Analyst, Industrial Research
+61 8 9224 6871 dwilliamson@argonaut.com

INSTITUTIONAL SALES - PERTH:
Chris Wippel | Executive Director, Head of Sales & Research
+61 8 9224 6875 cwippel@argonaut.com

John Sautel | Consultant, Sales & Research
+61 8 9224 6859 jsautel@argonaut.com

Damian Rooney | Director, Institutional Sales
+61 8 9224 6862 droney@argonaut.com

Ben Willoughby | Institutional Dealer
+61 8 9224 6813 bwilloughby@argonaut.com

PFI Russo | Institutional Dealer
+61 8 9224 6813 prusso@argonaut.com

Josh Welch | Institutional Dealer
+61 8 9224 6868 jwelch@argonaut.com

George Ogilvie | Institutional Dealer
+61 8 9224 6871 ogilvie@argonaut.com

INSTITUTIONAL SALES - HONG KONG:
Travis Smithson | Managing Director - Asia
+852 9832 0852 tsimih@argonaut.com

CORPORATE AND PRIVATE CLIENT SALES:
Glen Colgan | Executive Director, Desk Manager
+61 8 9224 6874 gcolgan@argonaut.com

Kevin Johnson | Executive Director, Corporate Stockbroking
+61 8 9224 6880 kjohnson@argonaut.com

James McGlew | Executive Director, Corporate Stockbroking
+61 8 9224 6866 jmcglew@argonaut.com

Ian Dorrington | Director, Corporate Stockbroking
+61 8 9224 6865 idorrington@argonaut.com

Geoff Barnsby-Johnson | Senior Dealer, Corporate Stockbroking
+61 8 9224 6854 gbj@argonaut.com

Rob Healy | Dealer, Private Clients
+61 8 9224 6873 rhealy@argonaut.com

Tony Locarno | Dealer, Private Clients
+61 8 9224 6851 tlocarno@argonaut.com

Cameron Pruonster | Dealer, Private Clients
+61 8 9224 6853 spruonster@argonaut.com

James Massey | Dealer, Private Clients
+61 8 9224 6845 jmassey@argonaut.com

Chris Hill | Dealer, Private Clients
+61 8 9224 6830 chil@argonaut.com

Important Disclosure
Argonaut acted as the Lead Manager to the Offer that raised $3.5M in June 2016 and received fees commensurate with this service. Argonaut holds or controls 12.1M BOT Options exercisable at $0.03 on or before 30 June 2019.

Argonaut Snapshot
Purpose of the report: It provides a background and overview, or update, for a Company that is typically at an early stage of its life cycle. Argonaut does provide a view and recommendation based on Company review, the outlook and management discussion.

What this report does not provide: As products and services for this type of business typically are yet to be firmly established, it is premature to model and forecast earnings and cash flow. In the absence of these forecasts, Argonaut therefore does not believe it appropriate to determine a valuation or set a target price.

RIS: There is a high degree of risk associated with a Company at an early stage of its life cycle. It is not certain whether the Company will be successful in establishing its products and/or services, or that it will be able to obtain the funding necessary to do so. Earnings and financial risks therefore must be considered high.

Information Disclosure
Each research analyst of this material certifies that the views expressed in this research material accurately reflect the analyst’s personal views about the subject securities and listed corporations. None of the listed corporations reviewed or any third party has provided or agreed to provide any compensation or other benefits in connection with this material to any of the analyst(s).

General Disclosure and Disclaimer
This research has been prepared by Argonaut Securities Pty Limited (ABN 72 108 330 650) (“ASPL”) or by Argonaut Securities (Asia) Limited (“ASAL”) for the use of the clients of ASPL, ASAL and other related bodies corporate (the “Argonaut Group”) and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this report in any way. ASPL is a holder of an Australian Financial Services License No. 274099 and is a Market Participant of the Australian Stock Exchange Limited. ASAL has a licence (AXO 052) to Deal and Advise in Securities and Advise on Corporate Finance in Hong Kong with its activities regulated by the Securities and Futures Ordinance (“SFO”) administered by the Securities and Futures Commission (“SFC”) of Hong Kong.

Nothing in this report should be construed as personal financial product advice for the purposes of Section 766B of the Corporations Act 2001 (Cth). This report does not consider any of your objectives, financial situation or needs. The report may contain general financial product advice and you should therefore consider the appropriateness of the advice having regard to your situation. We recommend you obtain financial, legal and taxation advice before making any financial investment decision.

This research is based on information obtained from sources believed to be reliable and ASPL and ASAL have made every effort to ensure the information in this report is accurate, but we do not make any representation or warranty that it is accurate, reliable, complete or up to date. The Argonaut Group accepts no obligation to correct or update the information or the opinions in it. Opinions expressed are subject to change without notice and accurately reflect the analyst(s)’ personal views at the time of writing. No member of the Argonaut Group or its respective employees, agents or consultants accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research.

Nothing in this research shall be construed as a solicitation to buy or sell any financial product, or to engage in or refrain from engaging in any transaction. The Argonaut Group and/or its associates, including ASPL, ASAL, officers or employees may have interests in the financial products or a relationship with the issuer of the financial products referred to in this report by acting in various roles including as investment banker, underwriter or dealer, holder of principal positions, broker, director or adviser. Further, they may buy or sell those securities as principal or agent, and as such may effect transactions which are not consistent with the recommendations (if any) in this research. The Argonaut Group and/or its associates, including ASPL and ASAL, may receive fees, brokerage or commissions for acting in those capacities and the reader should assume that this is the case.

There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment.

The analyst(s) principally responsible for the preparation of this research may receive compensation based on ASPL’s and/or ASAL’s overall revenues.

Hong Kong Distribution Disclosure
This material is being distributed in Hong Kong by Argonaut Securities (Asia) Limited which is licensed (AXO 052) and regulated by the Hong Kong Securities and Futures Commission. Further information on any of the securities mentioned in this material may be obtained on request, and for this purpose, persons in the Hong Kong office should be contacted at Argonaut Securities (Asia) Limited of Unit 701, 7/F, Henley Building, 5 Queen’s Road Central, Hong Kong, telephone (852) 3557 48000.

Copyright
© 2017. All rights reserved. No part of this document may be reproduced or distributed in any manner without the written permission of Argonaut Securities Pty Limited and/or Argonaut Securities (Asia) Limited. Argonaut Securities Pty Limited and Argonaut Securities (Asia) Limited specifically prohibits the re-writing permission of Argonaut Securities Pty Limited and/or Argonaut Securities (Asia) Limited.